[Cyclophosphamide therapy in kidney transplants].
D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection; D006505:Hepatitis / Q000201:enzymology; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D000637:Transaminases / Q000097:blood; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D003520:Cyclophosphamide; D000637:Transaminases; D001379:Azathioprine; D008775:Methylprednisolone
Cyclophosphamidtherapie bei Nierentransplantationen.